{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Evaluating CAR-T Therapy in Patients with Refractory B-Cell Lymphomas

Description

Method of Participation in the Learning Process/Evaluation Method

Successful completion of this activity includes reading the entire article and successfully completing the post-quiz and an evaluation form.

Getting the Most out of the Activity

As you prepare to participate in this activity, please reflect on your practice and your patients and identify clinical challenges you hope to have addressed.

While participating in the training, identify ways you can use newly acquired knowledge, strategies, and skills to enhance patient outcomes and your own professional development.

Purpose of Activity

To provide information on the use of autologous chimeric antigen receptor T-cell therapy (CAR-T) in patients with refractory B-cell lymphomas.

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Analyze the results of the Phase 2 trial of axicabtagene ciloleucel (axi-cel) for patients experiencing either resistance to primary or salvage-setting chemoimmunotherapy or a post-autologous stem cell transplant (ASCT) relapse.
  2. Assess implications for future research avenues and applications of this treatment.
Price: $10.00

Credits:

  • ACCME 1.0 CME

Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Lippincott Continuing Medical Education Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Professions: Physician
Test Code: OT0818
Published: Aug 2018
Expires: 7/31/2020
Sources: Oncology Times
Passing Score: 7/10 (70%)
Authors: Mr. Richard Simoneaux
Categories: Oncology
Specialties: Oncology